Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlokCompleted
NCT00539981Phase 3Updated Apr 6, 2022
Sponsor: Sanofi
Influenza
United States
Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine.Completed
NCT02697474Phase 3Updated Apr 6, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Hepatitis B
Thailand
Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in ChildrenCompleted
NCT03476135Phase 3Updated Apr 6, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningococcal Infections
Finland
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and OlderCompleted
NCT02842866Phase 3Updated Apr 5, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningitis · Meningococcal Meningitis · Meningococcal Infections
United States, Puerto Rico
Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate VaccineCompleted
NCT02752906Phase 3Updated Apr 5, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningitis · Meningococcal Meningitis · Meningococcal Infections
United States, Puerto Rico
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 YearsCompleted
NCT00788151Phase 2Updated Apr 5, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue Virus · Dengue Fever · Dengue Hemorrhagic Fever · Dengue Diseases
Peru
Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After BirthCompleted
NCT02428491Phase 3Updated Apr 5, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Diphtheria · Tetanus · Pertussis · Poliomyelitis
Vietnam
Efficacy and Safety of Dengue Vaccine in Healthy ChildrenCompleted
NCT00842530Phase 2Updated Apr 5, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue Virus · Dengue Fever · Dengue Hemorrhagic Fever · Dengue Diseases
Thailand
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in ToddlersCompleted
NCT02955797Phase 3Updated Apr 5, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningitis · Meningococcal Meningitis · Meningococcal Infections
Finland, Germany, Hungary, Spain
Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in ToddlersCompleted
NCT03205371Phase 3Updated Apr 5, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningitis, Meningococcal
Mexico, Russia, South Korea, Thailand
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy SubjectsCompleted
NCT00875524Phase 2Updated Apr 5, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue Virus · Dengue Fever · Dengue Hemorrhagic Fever · Dengue Disease
Vietnam
Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate VaccineCompleted
NCT02842853Phase 3Updated Apr 5, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningitis · Meningococcal Meningitis · Meningococcal Infections
United States
Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in IndiaCompleted
NCT01550289Phase 2Updated Apr 5, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue · Dengue Fever · Dengue Hemorrhagic Fever
India
DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected InfantsCompleted
NCT02817451Phase 3Updated Apr 5, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Diphtheria · Tetanus · Pertussis · Hepatitis B
South Africa
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy AdolescentsCompleted
NCT02199691Phase 2Updated Apr 4, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningitis · Meningococcal Meningitis · Meningococcal Infections
United States, Puerto Rico
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 YearsCompleted
NCT03233217Phase 1, Phase 2Updated Apr 4, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza
Japan
Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of AgeCompleted
NCT03698279Phase 2Updated Apr 4, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza
United States, Canada
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy ToddlersCompleted
NCT03205358Phase 2Updated Apr 4, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningitis · Meningococcal Meningitis · Meningococcal Infections
Finland
Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With AsthmaCompleted
NCT02573233Phase 2Updated Apr 4, 2022
Sponsor: Sanofi
Asthma
United States, Canada, Denmark, Germany, Sweden +1 more
Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and OlderCompleted
NCT01732627Phase 2Updated Apr 4, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Meningitis · Meningococcal Meningitis · Meningococcal Infections · Invasive Meningococcal Disease
United States
Pertussis Immunization Programs in Low Income Countries - Ivory CoastCompleted
NCT03388034N/AUpdated Apr 1, 2022
Sponsor: Institut Pasteur
Bordetella Pertussis, Whooping Cough
Côte d’Ivoire
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal ImpairmentUnknown
NCT05147493Phase 2Updated Mar 29, 2022
Sponsor: Hellenic Society of Hematology
Multiple Myeloma · Renal Impairment · Neoplasms, Plasma Cell · Neoplasms by Histologic Type
Greece
Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy StudyCompleted
NCT01983553N/AUpdated Mar 29, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Dengue · Dengue Fever · Dengue Hemorrhagic Fever
Thailand
Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)Completed
NCT03546192Phase 4Updated Mar 29, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza
Philippines
Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza VaccinesCompleted
NCT03308825Phase 4Updated Mar 29, 2022
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza · Flu
United States

Previous page Next page